Search
Prognostic genetic testing is recommended for all patients with chronic lymphocytic leukemia (CLL). However, recent research shows that testing is infrequently performed and outcomes poorer in patients with unfavorable disease risk.
By detecting molecular signatures in the blood, the sensor may help improve cancer screenings.
Memorial Sloan Kettering Cancer Center (MSK) experts shared the results of their latest research at the 65th American Society of Hematology (ASH) Annual Meeting, held in San Diego, December 9 to 12, 2023.
Learn about 14 students who will receive doctoral degrees from the Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences at MSK.
Memorial Sloan Kettering physicians have experience and specialized expertise in caring for people with uncommon cancers.
Thetis cells, a class of immune cells first described by MSK researchers in 2022, play an essential and previously unknown role in suppressing inflammatory responses to food, a new study finds.
The FDA has approved the targeted drug repotrectinib for patients 12 and older with tumors that carry gene changes called NTRK fusions. The trial that resulted in the approval was led by MSK investigators.
A prostate-specific antigen (PSA) test taken for the first time between the ages of 44 and 50 can predict the likelihood that a man will die from prostate cancer over the next 25 to 30 years, according to researchers at Memorial Sloan Kettering Cancer Center.
Pituitary adenomas continue to grow in a small subset of patients despite treatment with standard surgery and radiotherapy. Recognizing the significant unmet needs in this cohort, we recently published a review of the latest treatment options.